Creating a new biodegradable nanoparticle treatment for bladder cancer
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer
This study is testing a new treatment for bladder cancer that uses tiny, biodegradable particles to deliver medicine directly to cancer cells in the bladder, aiming to be safer and more effective than the current standard treatment, BCG, which can have side effects and is sometimes hard to get.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10853132 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for bladder cancer using biodegradable inorganic nanoparticles. These nanoparticles are designed to be administered directly into the bladder, where they can enter cancer cells and release substances that induce cell death. The goal is to provide a safer and more effective alternative to the current treatment, Bacille Calmette-Guérin (BCG), which can have significant side effects and is in short supply. By using these nanoparticles, the researchers aim to improve patient outcomes and reduce the need for more invasive procedures.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-risk non-muscle-invasive bladder cancer who are seeking alternative treatment options.
Not a fit: Patients with muscle-invasive bladder cancer or those who have already undergone radical cystectomy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for bladder cancer patients that is better tolerated and easier to produce than current therapies.
How similar studies have performed: While the use of nanoparticles in cancer treatment is a growing field, this specific approach using biodegradable inorganic nanoparticles for bladder cancer is relatively novel and has not been extensively tested.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Xie, Jin — University of Georgia
- Study coordinator: Xie, Jin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.